Related Experiment Video
Updated: Dec 9, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
New hints towards a precision medicine strategy for IDH wild-type glioblastoma
Abstract:
Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.
Insights
Glioblastoma (GBM) is a deadly brain cancer. Research into IDH-wild-type GBM subtypes and tumor microenvironments offers new avenues for precision therapies and improved patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer genomics
- Tumor microenvironment
Background:
- Glioblastoma (GBM) is the most common primary adult central nervous system malignancy, notoriously difficult to treat.
- Current subtyping efforts (mutational profiling, gene expression, DNA methylation) have not yet improved clinical outcomes for GBM patients.
- The IDH-wild-type GBM subset presents unique characteristics that may guide future therapeutic strategies.
Purpose of the Study:
- To review recent advancements in understanding IDH-wild-type glioblastoma.
- To explore how tumor microenvironment variations across GBM subtypes can be leveraged for novel therapeutic vulnerabilities.
- To discuss current and upcoming treatment approaches for IDH-wild-type glioblastoma.
Main Methods:
- Comprehensive literature review of recent glioblastoma research.
- Analysis of multi-omics data and single-cell technologies for subtype characterization.
- Integration of computational approaches for discovery and therapeutic strategy development.
Main Results:
- Subtyping IDH-wild-type glioblastoma reveals distinct molecular and microenvironmental profiles.
- Tumor microenvironment differences present potential targets for novel therapeutic interventions.
- Emerging knowledge from subtyping efforts offers promising directions for precision medicine in glioblastoma.
Conclusions:
- Understanding IDH-wild-type glioblastoma heterogeneity is crucial for advancing treatment.
- Targeting tumor microenvironment vulnerabilities across subtypes may overcome therapeutic resistance.
- An integrated discovery strategy combining multi-omics, single-cell, and computational methods is proposed for future glioblastoma research.
